152 related articles for article (PubMed ID: 2109297)
1. Tissue plasminogen activator for postvitrectomy fibrin formation.
Jaffe GJ; Abrams GW; Williams GA; Han DP
Ophthalmology; 1990 Feb; 97(2):184-9. PubMed ID: 2109297
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].
Zhao P; Wang W
Zhonghua Yan Ke Za Zhi; 1995 Jul; 31(4):255-8. PubMed ID: 8745515
[TBL] [Abstract][Full Text] [Related]
3. The use of tissue plasminogen activator in postvitrectomy cases.
Koutsandrea C; Apostolopoulos M; Theodossiadis P
Int Ophthalmol; 1993 Apr; 17(2):95-100. PubMed ID: 8407122
[TBL] [Abstract][Full Text] [Related]
4. Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator.
Jaffe GJ; Lewis H; Han DP; Williams GA; Abrams GW
Am J Ophthalmol; 1989 Aug; 108(2):170-5. PubMed ID: 2502924
[TBL] [Abstract][Full Text] [Related]
5. The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin.
Boldt HC; Abrams GW; Murray TG; Han DP; Mieler WF
Retina; 1992; 12(3 Suppl):S75-9. PubMed ID: 1455089
[TBL] [Abstract][Full Text] [Related]
6. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator.
Williams GA; Lambrou FH; Jaffe GA; Snyder RW; Green GD; Devenyi RG; Abrams GW
Arch Ophthalmol; 1988 Aug; 106(8):1055-8. PubMed ID: 3135790
[TBL] [Abstract][Full Text] [Related]
7. Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil.
MacCumber MW; McCuen BW; Toth CA; Ferrone PJ; Jaffe GJ
Ophthalmology; 1996 Feb; 103(2):269-73. PubMed ID: 8594513
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of recombinant plasminogen activator for intraocular fibrinolysis.
Koerner F; Boehnke M
Ger J Ophthalmol; 1992; 1(5):354-60. PubMed ID: 1477641
[TBL] [Abstract][Full Text] [Related]
9. Tissue plasminogen activator in the treatment of vitreoretinal diseases.
Kamei M; Estafanous M; Lewis H
Semin Ophthalmol; 2000 Mar; 15(1):44-50. PubMed ID: 10749314
[TBL] [Abstract][Full Text] [Related]
10. Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator.
Cellini M; Baldi A; Possati GL
Int Ophthalmol; 1994-1995; 18(6):351-3. PubMed ID: 7642335
[TBL] [Abstract][Full Text] [Related]
11. [Tissue plasminogen activator treatment of postvitrectomy pupillary fibrin membrane].
Maeno T; Maeda N; Ikeda T; Tano Y
Nippon Ganka Gakkai Zasshi; 1991 Nov; 95(11):1124-8. PubMed ID: 1759654
[TBL] [Abstract][Full Text] [Related]
12. Intraocular recombinant tissue-plasminogen activator fibrinolysis of fibrin formation after cataract surgery in children.
Klais CM; Hattenbach LO; Steinkamp GW; Zubcov AA; Kohnen T
J Cataract Refract Surg; 1999 Mar; 25(3):357-62. PubMed ID: 10079440
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic and prophylactic application of TPA (recombinant tissue plasminogen activator) into the anterior chamber of the eye].
Rehfeldt K; Höh H
Ophthalmologe; 1999 Sep; 96(9):587-93. PubMed ID: 10501987
[TBL] [Abstract][Full Text] [Related]
14. [Enzymatically induced posterior vitreous detachment in proliferative diabetic vitreoretinopathy].
Hesse L; Kroll P
Klin Monbl Augenheilkd; 1999 Feb; 214(2):84-9. PubMed ID: 10218200
[TBL] [Abstract][Full Text] [Related]
15. Complications of tissue plasminogen activator therapy after vitrectomy for diabetes.
Dabbs CK; Aaberg TM; Aguilar HE; Sternberg P; Meredith TA; Ward AR
Am J Ophthalmol; 1990 Oct; 110(4):354-60. PubMed ID: 2121038
[TBL] [Abstract][Full Text] [Related]
16. Effect of immediate postoperative intracameral tissue plasminogen activator (tPA) on anterior chamber fibrin formation in dogs undergoing phacoemulsification.
Mancuso LA; Nadelstein B; Berdoulay A; Spatola RA
Vet Ophthalmol; 2019 Jul; 22(4):477-484. PubMed ID: 30773778
[TBL] [Abstract][Full Text] [Related]
17. Endophthalmitis after pars plana vitrectomy. The Postvitrectomy Endophthalmitis Study Group.
Cohen SM; Flynn HW; Murray TG; Smiddy WE
Ophthalmology; 1995 May; 102(5):705-12. PubMed ID: 7777268
[TBL] [Abstract][Full Text] [Related]
18. Management of postvitrectomy diabetic vitreous hemorrhage with tissue plasminogen activator (t-PA) and volume homeostatic fluid-fluid exchanger.
Wu WC; Chang SM; Chen JY; Chang CW
J Ocul Pharmacol Ther; 2001 Aug; 17(4):363-71. PubMed ID: 11572467
[TBL] [Abstract][Full Text] [Related]
19. Treatment of total hyphema with relatively low-dose tissue plasminogen activator.
Kim MH; Koo TH; Sah WJ; Chung SM
Ophthalmic Surg Lasers; 1998 Sep; 29(9):762-6. PubMed ID: 9760614
[TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy.
Hesse L; Chofflet J; Kroll P
Ger J Ophthalmol; 1995 Nov; 4(6):323-7. PubMed ID: 8751095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
